Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Antiviral resistance and direct-acting antiviral agents for HCV
Author: Aloia, A.
Locarnini, S.
Beard, M.
Citation: Antiviral Therapy, 2012; 17(6 PART B):1147-1162
Publisher: Int Medical Press Ltd
Issue Date: 2012
ISSN: 1359-6535
Statement of
Amanda L Aloia, Stephen Locarnini, Michael R Beard
Abstract: Direct-acting antiviral (DAA) agents specifically target viral proteins. Two DAAs have been already been approved for the treatment of HCV infection and many more are in development. DAA treatment of HCV infection, however, leads to the selection of viral variants (produced by the error-prone HCV polymerase) that are resistant to the DAA agent in use. The selection of DAA-resistant HCV variants has been studied extensively in vitro and in vivo. Common amino acid substitution sites in each of the non-structural proteins are associated with DAA-resistance: D168, A155, A156 and V36 in NS3 protease; L31 and Y93 in NS5A; S282, S96, P495, M423, M414 and C316 in NS5B. In this review we cover the basic principles of DAA resistance, summarise the available resistance data for the various classes of DAAs and discuss the potential of DAA combination therapy for overcoming DAA-resistance, resulting in major advances in the treatment of HCV.
Keywords: Humans
Hepatitis C, Chronic
Viral Nonstructural Proteins
Antiviral Agents
Amino Acid Substitution
Drug Resistance, Viral
Virus Replication
Genome, Viral
Models, Molecular
RNA-Dependent RNA Polymerase
Rights: © International Medical Press
DOI: 10.3851/IMP2426
Grant ID:
Published version:
Appears in Collections:Aurora harvest
Molecular and Biomedical Science publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.